Slide 1: IMU-856: Dose-Dependent Increase of GLP-1 in Patients
Slide 2: Cautionary Note Regarding Forward-Looking Statements
Cautionary Note Regarding Forward-Looking Statements This presentation contains “forward-looking statements” that involve substantial risks and uncertainties for purposes of the safe harbor within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21 of the Securities
Slide 3: IMU-856 Targets Physiological Intestinal Epithelial Regeneration and Restoration of Gut Cell Function
IMU-856 Targets Physiological Intestinal Epithelial Regeneration and Restoration of Gut Cell Function = Innovative oral therapeutic approach potentially applicable to a broad range of gastrointestinal disorders = Targets physiological intestinal epithelial regeneration, including gut hormon-producin
Slide 4: Intestinal Production of GLP-1 Mediates Effects on Body Weight
Intestinal Production of GLP-1 Mediates Effects on Body Weight Ov . . Main Physiologic Effects of GLP-1 GLP-1: Glucagon-Like Peptide-1 GLP-1 = Peptide hormone generated through enzymatic breakdown of proglucagon = Endocrine hormone, secreted by enteroendocrine L-cells located in the distal jejunum,
Slide 5: IMU-856: Effects on Body Weight in Preclinical Experiment and on Blood GLP-1 Levels in Celiac Disease Clinical Trial
IMU-856: Effects on Body Weight in Preclinical Experiment and on Blood GLP-1 Levels in Celiac Disease Clinical Trial SS 6-Months /n Vivo Study Phase 1b Clinical Trial of IMU-856 = Regulated GLP study"! to support clinical development = Designed to explore effects of gluten challenge in a celiac * Da
Slide 6: In a 6-Months In Vivo Study, IMU-856 Dose-Dependently Reduced Weight Gain
In a 6-Months /n Vivo Study, IMU-856 Dose-Dependently Reduced Weight Gain Body Weight - % Change From Baseline Dose-dependent effect on body weight gain Linked to reduced food consumption Effect in both males and females No effect on general health condition 2 40 60 80 10 1% 1 16 19 20 Study day 10
Slide 7: Confirmation of Effects as Part of Phase 1b Clinical Trial: IMU-856 Dose-Dependently Increased GLP-1 in Celiac Disease Patients
Confirmation of Effects as Part of Phase 1b Clinical Trial: IMU-856 Dose-Dependently Increased GLP-1 in Celiac Disease Patients 28-day phase 1b clinical trial of IMU-856 in celiac disease GLP-1 Plasma Concentration = Patients measured for plasma GLP-1 concentrations: Median % Change from Baseline to
Slide 8: IMU-856 Demonstrated Functional Improvement of Gut Epithelial Cells in Phase 1b Clinical Trial in Celiac Disease Patients
IMU-856 Demonstrated Functional Improvement of Gut Epithelial Cells in Phase 1b Clinical Trial in Celiac Disease Patients Improved Uptake of Actively Transported Essential Nutrient Vitamin B12 Protected Against Gluten-Induced Decrease in Villous Height Mean change from Baseline to Day 29 in vitamin
Slide 9: SIRT6 Target Is Highly Expressed in Gut Epithelial Cells
SIRT6 Target Is Highly Expressed in Gut Epithelial Cells G Highest mRNA Expressions in Paneth Cells, Enterocytes, © Goblet Cells and Enteroendocrine Cells such as L-Cells ye jm li é ‘ esc Macrophage Left: tp: //wrw.prowinatlas.or// Right: Peterson, L, Arts D. Nat Rev Immunol 14, 141-153 (2014) SIRT:
Slide 10: Main Secretory Epithelial Cells of the Bowel Epithelium
Main Secretory Epithelial Cells of the Bowel Epithelium All Have Been Shown to Express SIRT6 Target Produce and release a protective mucus layer, with the main = so component of this mucus being a protein called mucin 2 a Goblet = cell = a 5 ot Secret gastrointestinal hormones: such as gastric inhib
Slide 11: IMU-856: A Novel Mechanism Offering Potential to Go Beyond Existing GLP-1, GLP-2, GIP Mimetics
IMU-856: A Novel Mechanism Offering Potential to Go Beyond Existing GLP-1, GLP-2, GIP Mimetics G SIRT6 Targeting Approach S Incretin Mimetics IMU-856 GLP-1, GLP-2, GIP = Functional improvement of = Providing synthetic peptides that mimic the enteroendocrine and other epithelial cells natural hormone
Slide 12: Obesity Market Expected to Reach More Than $170 Billion Globally by 2031
Obesity Market Expected to Reach More Than $170 Billion Globally by 2031! 7A Unmet Needs Still Exist to Address This Growing call Medical Challenge = Obesity and overweight are among the fastest growing and most prevalent chronic human conditions in the world affecting ~2.5 billion adults worldwide!
Slide 13: IMU-856's GLP-1 Effect: Summary and Outlook
IMU-856’s GLP-1 Effect: Summary and Outlook Dose-dependent reduction of body weight gain of up to -40 % observed in preclinical study Dose-dependent increase of endogenous GLP-1 levels of up to 2.5 times versus placebo observed in celiac disease phase 1b clinical trial Typical physiological increase
Slide 14: Q&A Session
Slide 15: Thank You!
Thank You! Jessica Breu Vice President Investor Relations & Communications G Phone: +1-332-255-9819 ©& Email: ir@imux.com © Web: www.imux.com 15 | © immunic, inc. | Feb/20/2025 Immunic, Inc. 1200 Avenue of the Americas New York City, NY 10036 USA Immunic AG Lochhamer Schlag 21 82166 Grafelfing (Muni